Media contact: Stéphanie Bardon – communication@genethon.fr – 01.69.47.12.78
February 15, 2010
An effective gene therapy approach for dysferlin deficiencies
Research scientists at Généthon find a solution to the problem of the dysferlin gene’s size to transport it into muscle.
(read more)June 16, 2009
Thermo Fischer Scientific 2009 prize
Anne Galy, winner of the Biotherapy prize for her project “gene therapy in Wiskott-Aldrich syndrome”
(read more)February 20, 2009
Gene therapy: Production of the first batch of HIV-derived vectors in Europe for use in a human clinical trial
Genethon, the laboratory created and funded by the AFM (French Association against Myopathies) using donations from Téléthon, today announced that it has produced, controlled and released a batch of lentiviral vectors derived from the human immunodeficiency (HIV) virus for a gene therapy trial in humans in a rare immune deficiency. The… (read more)
February 12, 2008
Neuromuscular diseases: A pharmacological therapeutic approach for certain sarcoglycanopathies
A research team led by Dr Isabelle Richard (CNRS-FRE3087) from the Genethon laboratory financed by the AFM through Téléthon donations has just demonstrated the efficacy of a novel pharmacological strategy in the mouse for certain mutations of alpha-sarcoglycanopathy or LGMD2D, a recessive limb girdle dystrophy. This pharmacological strategy… (read more)
